N-3 long-chain polyunsaturated fatty acids inhibit smooth muscle cell migration by modulating urokinase plasminogen activator receptor through MEK/ERK-dependent and -independent mechanisms

Journal of Nutritional Biochemistry

Volumn 23, Issue 11, 2012, Pages 1378-1383

  Whyte, Claire ^a   Thies, Frank ^a,b   Peyrol, Lise ^a   Balcerzak, Denis ^a  

^a ROWETT RESEARCH INSTITUTE   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Aortic smooth muscle cells; Docosahexaenoic acid; Eicosapentaenoic acid; MEK ERK; Migration; Urokinase plasminogen activator receptor

Indexed keywords

DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; OMEGA 3 FATTY ACID; PHOSPHOLIPID; PLASMIN; SMALL INTERFERING RNA; UROKINASE; UROKINASE RECEPTOR;

ADOLESCENT; ADULT; ARTICLE; CELL MIGRATION; DRUG MECHANISM; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MALE; PHENOTYPE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; WESTERN BLOTTING;

ADOLESCENT; ADULT; CELL MOVEMENT; CELLS, CULTURED; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; MYOCYTES, SMOOTH MUSCLE; PHENOTYPE; PHOSPHOLIPIDS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84867698117     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2011.08.005     Document Type: Article

References (54)

1. Newby A.C., Zaltsman A.B. Fibrous cap formation or destruction-the critical importance of vascular smooth muscle cell proliferation, migration and matrix formation. Cardiovasc Res 1999, 41:345-360.
2. Manderson J., Mosse P., Safstrom J., Young S., Campbell G. Balloon catheter injury to rabbit carotid artery. I. Changes in smooth muscle phenotype. Arterioscler Thromb Vasc Biol 1989, 9:289-298.
3. Pietilä T., Nikkari T. Enhanced synthesis of collagen and total protein by smooth muscle cells from atherosclerotic rabbit aortas in culture. Atherosclerosis 1980, 37:11-19.
4. Plenz G.A.M., Deng M.C., Robenek H., Völker W. Vascular collagens: spotlight on the role of type VIII collagen in atherogenesis. Atherosclerosis 2003, 166:1-11.
5. Jackson C.L., Raines E.W., Ross R., Reidy M.A. Role of endogenous platelet-derived growth factor in arterial smooth muscle cell migration after balloon catheter injury. Arterioscler Thromb Vasc Biol 1993, 13:1218-1226.
6. Prescott M.F., Webb R.L., Reidy M.A. Angiotensin-converting enzyme inhibitor versus angiotensin II, AT1 receptor antagonist: effects on smooth muscle cell migration and proliferation after balloon catheter injury. Am J Pathol 1991, 139:1291-1296.
7. Jackson C.L., Reidy M.A. Basic fibroblast growth factor: its role in the control of smooth muscle cell migration. Am J Pathol 1993, 143:1024-1031.
8. Koyama N., Harada K., Yamamoto A., Morisaki N., Saito Y., Yoshida S. Purification and characterization of an autocrine migration factor for vascular smooth muscle cells (SMC), SMC-derived migration factor. J Biol Chem 1993, 268:13301-13308.
9. Wolf Y.G., Rasmussen L.M., Ruoslahti E. Antibodies against transforming growth factor-β1 suppress intimal hyperplasia in a rat model. J Clin Invest 1994, 93:1172-1178.
10. Gerthoffer W.T. Mechanisms of vascular smooth muscle cell migration. Circ Res 2007, 100:607-621.
11. Reuning U., Dixon E.P., Little S.P., Bang N.U. Mitogen crosstalk accompanying urokinase receptor expression in stimulated vascular smooth muscle cells. FEBS Lett 1996, 392:125-128.
12. Bessard A., Frémin C., Ezan F., Coutant A., Baffet G. MEK/ERK-dependent uPAR expression is required for motility via phosphorylation of P70S6K in human hepatocarcinoma cells. J Cell Physiol 2007, 212:526-536.
13. Kenagy R.D., Vergel S., Mattsson E., Bendeck M., Reidy M.A., Clowes A.W. The role of plasminogen, plasminogen activators, and matrix metalloproteinases in primate arterial smooth muscle cell migration. Arterioscler Thromb Vasc Biol 1996, 16:1373-1382.
14. Carmeliet P., Moons L., Herbert J., Crawley J., Lupu F., Lijnen R., et al. Urokinase but not tissue plasminogen activator mediates arterial neointima formation in mice. Circ Res 1997, 81:829-839.
15. Okada S.S., Grobmyer S.R., Barnathan E.S. Contrasting effects of plasminogen activators, urokinase receptor, and LDL receptor-related protein on smooth muscle cell migration and invasion. Arterioscler Thromb Vasc Biol 1996, 16:1269-1276.
16. Okada S.S., Tomaszewski J.E., Barnathan E.S. Migrating vascular smooth muscle cells polarize cell surface urokinase receptors after injury in vitro. Exp Cell Res 1995, 217:180-187.
17. Stoppelli M.P., Corti A., Soffientini A., Cassani G., Blasi F., Assoian R.K. Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc Natl Acad Sci USA 1985, 82:4939-4943.
18. GISSI-Prevenzione Investigators Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999, 354:447-455.
19. Newman W.P., Middaugh J.P., Propst M.T., Rogers D.R. Atherosclerosis in Alaska natives and non-natives. Lancet 1993, 341:1056-1057.
20. Mizutani M., Asano M., Roy S., Nakajima T., Soma M., Yamashita K., et al. ω-3 polyunsaturated fatty acids inhibit migration of human vascular smooth muscle cells in vitro. Life Sci 1997, 61:269-274.
21. Isbilen B., Fraser S.P., Djamgoz M.B.A. Docosahexaenoic acid (omega-3) blocks voltage-gated sodium channel activity and migration of MDA-MB-231 human breast cancer cells. Int J Biochem Cell Biol 2006, 38:2173-2182.
22. Thies F., Pillon C., Moliere P., Lagarde M., Lecerf J. Preferential incorporation of sn-2 lysoPC DHA over unesterified DHA in the young rat brain. Am J Physiol Regul Integr Comp Physiol 1994, 267:R1273-R1279.
23. Thies F., Nebe-von-Caron G., Powell J.R., Yaqoob P., Newsholme E.A., Calder P.C. Dietary supplementation with eicosapentaenoic acid, but not with other long-chain n_3 or n_6 polyunsaturated fatty acids, decreases natural killer cell activity in healthy subjects aged >55 y. Am J Clin Nutr 2001, 73:539-548.
24. Morgan A.R., Rerkasem K., Gallagher P.J., Zhang B., Morris G.E., Calder P.C., et al. Differences in matrix metalloproteinase-1 and matrix metalloproteinase-12 transcript levels among carotid atherosclerotic plaques with different histopathological characteristics. Stroke 2004, 35:1310-1315.
25. Castellxó R., Estellés A., Vázquez C., Falcó C., España F., Almenar S.M., et al. Quantitative real-time reverse transcription-PCR assay for urokinase plasminogen activator, plasminogen activator inhibitor type I, and tissue metalloproteinase inhibitor type I gene expressions in primary breast cancer. Clin Chem 2002, 48:1288-1295.
26. Bligh E.G., Dyer W.J. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959, 37:911-917.
27. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nuc Acids Res 2001, 29:e45.
28. Pfaffl M.W., Horgan G.W., Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucl Acids Res 2002, 30:e36.
29. Delbosc S., Glorian M., Le Port A., Bereziat G., Andreani M., Limon I. The benefit of docosahexanoic acid on the migration of vascular smooth muscle cells is partially dependent on Notch regulation of MMP-2/-9. Am J Pathol 2008, 172:1430-1440.
30. Weber C., Erl W., Pietsch A., Danesch U., Weber P.C. Docosahexaenoic acid selectively attenuates induction of vascular cell adhesion molecule-1 and subsequent monocytic cell adhesion to human endothelial cells stimulated by tumor necrosis factor-alpha. Arterioscler ThrombVasc Biol 1995, 15:622-628.
31. Schley P.D., Brindley D.N., Field C.J. (n-3) PUFA alter raft lipid composition and decrease epidermal growth factor receptor levels in lipid rafts of human breast cancer cells. J Nutr 2007, 137:548-553.
32. Fischer S., Vischer A., Preac-Mursic V., Weber P.C. Dietary docosahexaenoic acid is retroconverted in man to eicosapentaenoic acid, which can be quickly transformed to prostaglandin I3. Prostaglandins 1987, 34:367-375.
33. 2+ concentration and membrane potential in vascular smooth muscle cells. Atherosclerosis 1998, 138:117-127.
34. Von Schacky C., Weber P.C. Metabolism and effects on platelet function of the purified eicosapentaenoic and docosahexaenoic acids in humans. J Clin Invest 1985, 76:2446-2450.
35. Clowes A., Schwartz S. Significance of quiescent smooth muscle migration in the injured rat carotid artery. Circ Res 1985, 56:139-145.
36. Owens G.K. Expression of smooth muscle-specific alpha-isoactin in cultured vascular smooth muscle cells: relationship between growth and cytodifferentiation. J Cell Biol 1986, 102:343-352.
37. Kavurma M.M., Khachigian L.M. ERK, JNK, and p38 MAP kinases differentially regulate proliferation and migration of phenotypically distinct smooth muscle cell subtypes. J Cell Biochem 2003, 89:289-300.
38. Denger S., Jahn L., Wende P., Watson L., Gerber S.H., Kübler W., et al. Expression of monocyte chemoattractant protein-1 cDNA in vascular smooth muscle cells: induction of the synthetic phenotype: a possible clue to SMC differentiation in the process of atherogenesis. Atherosclerosis 1999, 144:15-23.
39. Florentin R.A., Nam S.C., Daoud A.S., Jones R., Scott R.F., Morrison E.S., et al. Dietary-induced atherosclerosis in miniature swine. Exp Mol Pathol 1968, 8:263-301.
40. Stary H.C., Malinow M.R. Ultrastructure of experimental coronary artery atherosclerosis in cynomolgus macaques: a comparison with the lesions of other primates. Atherosclerosis 1982, 43:151-175.
41. Ang A.H., Tachas G., Campbell J.H., Bateman J.F., Campbell G.R. Collagen synthesis by cultures rabbit aortic smooth-muscle cells: alteration with phenotype. Biochem J 1990, 265:461-469.
42. Shukla N., Rowe D., Hinton J., Angelini G.D., Jeremy J.Y. Calcium and the replication of human vascular smooth muscle cells: studies on the activation and translocation of extracellular signal regulated kinase (ERK) and cyclin D1 expression. Eur J Pharmacol 2005, 509:21-30.
43. Sobue K., Hayashi K., Nishida W. Molecular mechanism of phenotypic modulation of smooth muscle cells. Horm Res 2000, 50:15-24.
44. Kiyan J., Kush A., Tkachuk S., Krämer J., Haller H., Dietz R Smith G., et al. Rosuvastatin regulates vascular smooth muscle cell phenotypic modulation in vascular remodelling: role for the urokinase receptor. Atherosclerosis 2007, 195:254-261.
45. Takeda K., Ichiki T., Tokunou T., Iino N., Takeshita T. 15-Deoxy-_12,14-prostaglandin J2 and thiazolidinediones activate the MEK/ERK pathway through phosphatidylinositol 3-kinase in vascular smooth muscle cells. J Biol Chem 2001, 276:48950-48955.
46. Levy B.D. Resolvins and protectins: natural pharmacophores for resolution biology. Prostaglandins Leukot Essent Fatty Acids 2010, 82:327-332.
47. Noda-Heiny H., Daugherty A., Sobel B.E. Augmented urokinase receptor expression in atheroma. Arterio Thromb Vasc Biol 1995, 15:37-43.
48. Odekon L.E., Sato Y., Rifkin D.B. Urokinase-type plasminogen activator mediates basic fibroblast growth factor-induced bovine endothelial cell migration independent of its proteolytic activity. J Cell Physiol 1992, 150:258-263.
49. Del Rosso M., Fibbi G., Dini G., Grappone C., Pucci M., Cladini R., et al. Role of specific membrane receptors in urokinase-dependent migration of human keratinocytes. J Invest Dermatol 1990, 94:310.
50. Stahl A., Mueller B.M. Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro. Cancer Res 1994, 54:3066-3071.
51. r receptor protein for urokinase-type plasminogen activator. J Biol Chem 1988, 263:2358-2363.
52. Behrendt N., Ronne E., Ploug M., Petri T., Lober D., Nielsen L.S., et al. The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants. J Biol Chem 1990, 265:6453-6460.
53. Estreicher A., Wohlwend A., Belin D., Schleuning W., Vassalli J. Characterization of the cellular binding site for the urokinase-type plasminogen activator. J Biol Chem 1989, 264:1180-1189.
54. Sidenius N., Sier C.F.M., Blasi F. Shedding and cleavage of the urokinase receptor (uPAR): identification and characterisation of uPAR fragments in vitro and in vivo. FEBS Lett 2000, 475:52-56.